Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 17. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir or its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO....
Source: Expert Review of Clinical Pharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 17. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir or its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO....
Source: Pharmacological Reviews - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 17. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir or its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO....
Source: Expert Review of Clinical Pharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 17. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir or its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO....
Source: Pharmacological Reviews - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 17. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir or its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO....
Source: Expert Review of Clinical Pharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 22:1-12. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir, its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. W...
Source: Expert Review of Clinical Pharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 22:1-12. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir, its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. W...
Source: Expert Review of Clinical Pharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
Prenatal Care: An Evidence-Based Approach
Am Fam Physician. 2023 Aug;108(2):139-150.ABSTRACTWell-coordinated prenatal care that follows an evidence-based, informed process results in fewer hospital admissions, improved education, greater satisfaction, and lower pregnancy-associated morbidity and mortality. Care initiated at 10 weeks or earlier improves outcomes. Identification and treatment of periodontal disease decreases preterm delivery risk. A prepregnancy body mass index greater than 25 kg per m2 is associated with gestational diabetes mellitus, hypertension, miscarriage, and stillbirth. Advanced maternal and paternal age (35 years or older) is associated wit...
Source: American Family Physician - August 17, 2023 Category: Primary Care Authors: Sarah In és Ramírez Source Type: research
Prenatal Care: An Evidence-Based Approach
Am Fam Physician. 2023 Aug;108(2):139-150.ABSTRACTWell-coordinated prenatal care that follows an evidence-based, informed process results in fewer hospital admissions, improved education, greater satisfaction, and lower pregnancy-associated morbidity and mortality. Care initiated at 10 weeks or earlier improves outcomes. Identification and treatment of periodontal disease decreases preterm delivery risk. A prepregnancy body mass index greater than 25 kg per m2 is associated with gestational diabetes mellitus, hypertension, miscarriage, and stillbirth. Advanced maternal and paternal age (35 years or older) is associated wit...
Source: American Family Physician - August 17, 2023 Category: Primary Care Authors: Sarah In és Ramírez Source Type: research
Prenatal Care: An Evidence-Based Approach
Am Fam Physician. 2023 Aug;108(2):139-150.ABSTRACTWell-coordinated prenatal care that follows an evidence-based, informed process results in fewer hospital admissions, improved education, greater satisfaction, and lower pregnancy-associated morbidity and mortality. Care initiated at 10 weeks or earlier improves outcomes. Identification and treatment of periodontal disease decreases preterm delivery risk. A prepregnancy body mass index greater than 25 kg per m2 is associated with gestational diabetes mellitus, hypertension, miscarriage, and stillbirth. Advanced maternal and paternal age (35 years or older) is associated wit...
Source: American Family Physician - August 17, 2023 Category: Primary Care Authors: Sarah In és Ramírez Source Type: research
Prenatal Care: An Evidence-Based Approach
Am Fam Physician. 2023 Aug;108(2):139-150.ABSTRACTWell-coordinated prenatal care that follows an evidence-based, informed process results in fewer hospital admissions, improved education, greater satisfaction, and lower pregnancy-associated morbidity and mortality. Care initiated at 10 weeks or earlier improves outcomes. Identification and treatment of periodontal disease decreases preterm delivery risk. A prepregnancy body mass index greater than 25 kg per m2 is associated with gestational diabetes mellitus, hypertension, miscarriage, and stillbirth. Advanced maternal and paternal age (35 years or older) is associated wit...
Source: American Family Physician - August 17, 2023 Category: Primary Care Authors: Sarah In és Ramírez Source Type: research
